Ocugen ($OCGN): What Happens at the October 5 Shareholder Vote?

21 Bull, base and bear scenarios

These are reading frames, not forecasts, and none of them is a recommendation. Each is written so that a reader can say which document would confirm or break it.

What makes Ocugen unusual is that the binary event in front of it is procedural rather than scientific. A trial result is unknowable in advance; a shareholder vote is not, quite — the electorate is fixed at the July 27 record date, the threshold is arithmetic, brokers have discretion on this item, and 47.3 per cent of the shares already turned up once. The company needs 50 per cent plus one of everything, and abstention is indistinguishable from opposition.

What Would Falsify This Reading

The reading on this page is that the October 5 vote is the binding constraint, that the convertible notes are the reason it binds, and that the clinical programmes are real but far from revenue. Each of the following would damage that reading, and each is checkable.

• The threshold is arithmetic, and the first attempt fell short of it. A majority of all 339,110,401 outstanding shares is 169,555,201. Shares represented on September 21 were 160,214,431. Abstentions count as votes against, and the company itself says it does not expect broker non-votes because brokers have discretion on this proposal — so the gap cannot be closed by routing. If the proposal passes on October 5, turnout rose; nothing else can have changed.
• The cash-settlement feature is in the filing, not inferred. The June-quarter report states that the notes are “not convertible prior to the earlier of May 15, 2027 and the Reserved Share Effective Date” and that “unless and until the Reserved Share Effective Date occurs the Company is required to settle conversions solely in cash.” That single clause is why $82.4 million of an eight-year note sits in current liabilities beside a $33.7 million derivative liability, and therefore why equity is negative.
• The going-concern conclusion is the company’s own, in the present tense. Verbatim: “the Company has concluded that there is substantial doubt about the Company’s ability to continue as a going concern within one year after the date these condensed consolidated financial statements are issued.” The auditor attached a separate explanatory section saying the same in the annual report. A reader who has only seen the press-release phrase “extending cash runway into 2028” has seen one of two statements the company published about the same balance sheet.
• Or the capital question is already solved and the page overstates it. This is the strongest argument the other way. Cash went from $18.6 million to $100.1 million in six months; the 12.25 per cent secured loan was repaid and terminated in May and the lien released; operating cash use in the June quarter was $12.2 million, which on $100.1 million is a long time; and the notes do not mature until 2034, with the first holder put in May 2032. On that reading the current-liability classification is an accounting consequence of a clause that one shareholder vote removes, not a cash obligation anyone expects to pay in 2026.
• The clinical record is further from revenue than the designations suggest. No licence application has been submitted for any programme. There is no PDUFA date, no advisory committee and no application under review; the company’s own plan puts the first submission in 2Q 2027, after topline in 1Q 2027. The Bahamian grant is an expanded-access authorisation gated on a further full approval. And on the one pivotal trial with an interim already read, the monitoring committee recorded a negative direction of treatment effect.

None of these is a prediction. They are the observations that would make the rest of this page wrong, listed so that a reader can check them rather than take the reading on trust.

01 Executive answer: what the vote decides

Six facts set the frame, and the first one is the whole file.

October 5 is not a new meeting and there is only one item left on it. The special meeting convened on September 21, 2026 and was adjourned “solely with respect to” the proposal to raise authorised common stock by 250,000,000 shares, from 390,000,000 to 640,000,000. The board approved it on July 16, 2026 and recommends it unanimously. The second item on that ballot — permission to adjourn and solicit more votes — passed and produced the October date.

It needs a majority of every outstanding share, and the first attempt did not have the votes in the room. The standard is a majority of the voting power of all then-outstanding shares entitled to vote, which on 339,110,401 shares is 169,555,201. Shares represented on September 21 totalled 160,214,431, or 47.3 per cent. Quorum is one third, so the meeting was valid; passing is a different number. Abstentions have the same effect as votes against.

The reason it matters is $130 million of convertible notes. Issued in May 2026 at 6.75 per cent, due 2034, with a conversion price of about $2.68. Until the authorised-share increase takes effect, the company is required to settle any conversion solely in cash, and Nasdaq’s shareholder-approval rule caps share settlement at 67,629,947 shares. The indenture obliged the company to hold this vote by September 30, 2026 — a date now passed, leaving a “best efforts” obligation in its place.

The company has already promised more shares than it is authorised to issue. 339,044,893 outstanding at June 30 plus 122,396,448 potentially dilutive securities is about 461.6 million — a calculation — against 390,000,000 authorised. Separately, a letter agreement of January 20, 2026 gives the chief executive the right, if no amendment is approved by December 31, 2026, to settle certain performance units and options in cash, with the company paying interest on those amounts and a tax gross-up; 2,000,000 of his options are suspended until the increase is effective.

Two statements about the same balance sheet are both in the record. The press release of August 6, 2026 says the note financing “extends Ocugen’s cash runway into 2028.” The quarterly report filed the same day concludes that there is “substantial doubt about the Company’s ability to continue as a going concern within one year.” Cash is $100.1 million; total liabilities $140.8 million; shareholders’ equity minus $16.6 million; accumulated deficit $452.1 million.

No regulator is waiting on anything. There is no licence application submitted for any programme, so no goal date, no advisory committee and no decision pending. The company’s plan is OCU400 topline in 1Q 2027 and a submission in 2Q 2027. The only revenue is a non-cash collaborative item of about $1.5 million a quarter.

02 The vote, the arithmetic and the threshold

Why the company says it wants the shares

The stated reasons are in the proxy and worth quoting rather than paraphrasing. The general one: “The ability to issue equity is fundamental to our growth strategy… to provide us with appropriate flexibility to issue additional shares in the future on a timely basis if such need arises in connection with potential financings, business combinations, licensing arrangements or other corporate purposes.” A reader should notice that financings are named first.

The specific one is the note indenture, and the proxy sets it out plainly: the company “agreed to hold a stockholders’ meeting no later than September 30, 2026” to obtain approval for either a share increase or a reverse split sufficient to cover the maximum conversion shares, and “if we do not obtain the stockholder approval… on or prior to September 30, 2026, we are obligated to use our best efforts to obtain such approval as soon as possible.” Approval “would also ensure that we will have the option to settle conversion of the Notes in shares of common stock instead of cash.”

And the third reason is personal to the chief executive, disclosed in the proxy as an interest in the outcome. Under a letter agreement dated January 20, 2026, if shareholders do not approve an amendment of this kind by December 31, 2026, he “will be entitled to settle certain PSUs and stock options in cash upon vesting and exercise… and we would be required to pay interest on the cash settlement amounts as well as a tax gross-up.” The covered awards are specific: 2,000,000 of the 3,123,201 options granted January 2, 2026, 6,000,000 of the 9,369,604 performance units granted the same day, and 1,000,000 of the 1,388,889 2025 performance units. The exercisability of those 2,000,000 options is suspended until an authorised share increase becomes effective, with the option term extending automatically if the suspension runs long.

A reverse split is not on this ballot, but the indenture would have accepted one

The proxy is explicit that no reverse stock split and no equity-plan increase is being voted on. A reverse split appears only as the alternative the indenture would also have satisfied, because either route produces enough authorised and unissued shares. That matters for what a failed vote implies: the obligation is to create reservable shares, and if the register will not authorise more of them, the arithmetic can be solved from the other direction instead.

There is one precedent for a reverse split here, and it is old and structural rather than a bid-price rescue: a 1-for-60 reverse split effected September 27, 2019, immediately before the reverse merger that turned Histogenics Corporation into Ocugen. Roughly 1.6 million shares were outstanding immediately after it, before the merger consideration was issued. The ticker changed on September 30, 2019. No other split, forward or reverse, appears in the company’s filings.

The authorised-share history, which is why a Delaware court got involved

Authorised common has been raised twice in recent years: to 295,000,000 following an April 2021 shareholder approval, and to 390,000,000 in July 2024 (total authorised capital 400,000,000 including the 10,000,000 preferred). That second increase became a legal problem. In October 2025 a class action was filed in the Delaware Court of Chancery alleging the company “breached provisions of the Company’s charter and attempted to evade the voting threshold in the Company’s charter.” On February 12, 2026 Ocugen petitioned the same court under Section 205 of the Delaware General Corporation Law to validate the amendment and every share issued in reliance on it. At a hearing on May 6, 2026 the court validated the certificate of amendment and declared valid all shares issued after its effectiveness on July 11, 2024, and in July 2026 the class action was dismissed as moot, with the court retaining jurisdiction over a possible fee application.

That history is not decoration. It is the reason the current proposal is being run as a standalone special meeting with an explicit threshold statement, and it is the reason a reader should treat the voting standard as the operative fact rather than an administrative detail.

03 The convertible notes and the cash-settlement trap

Everything odd about this balance sheet comes from one instrument and one clause inside it. The instrument is ordinary enough; the clause is what turns an eight-year note into a current liability and a $100 million cash pile into a going-concern question.

What the notes replaced, which is the part that improved

The note proceeds retired a materially worse instrument. The Avenue Capital loan and security agreement of November 2024 carried a variable rate at “the greater of the prime rate plus 4.25 per cent or 12.25 per cent,” was secured by a senior lien over substantially all assets with a negative pledge on the intellectual property, and gave the lenders the right to convert up to $6.0 million of principal at 80 per cent of the trading price on the date of conversion — a floorless conversion feature, capped together with an equity grant at 19.9 per cent of the outstanding shares. A resale shelf had been filed registering up to 57,542,768 shares against that right. It was repaid in full on May 7, 2026, the facility and all loan documents terminated, the lien released and every conversion right extinguished, at a cost of a $2.4 million loss on extinguishment.

Trading a floorless 12.25 per cent secured convertible for a fixed 6.75 per cent unsecured note struck 45 per cent above market is, on its own terms, a clear improvement. The cost of it is the clause above.

The rest of the debt, and what is not there

The only other borrowing is small and unusual: an EB-5 loan facility originally dated September 2016, drawn in increments at a fixed 4.0 per cent, with each draw due on the seventh anniversary of its disbursement, secured over substantially all assets except the intellectual property. Principal outstanding at June 30, 2026 is $1,500 thousand, carrying value $1,749 thousand including accrued interest. The facility was amended in May 2023 to raise capacity to $20.0 million in $0.8 million increments, and nothing has been drawn under the amended offering.

What is absent is worth stating plainly. There is no at-the-market programme of any kind — the annual report contains zero occurrences of the phrase, and no sales agreement appears in any filing. There is no synthetic-royalty, revenue-interest or royalty-monetisation facility; the only item of the kind in the record is historic and immaterial — the annual report attributes $0.8 million of lifetime funding to “the royalty agreement.” And there are no pre-funded warrants: every warrant outstanding is an ordinary exercise-price warrant. For a company at this price point, the absence of an at-the-market facility is unusual, and it means equity issuance has to come through announced transactions rather than quietly through the tape.

How the money was actually raised

Two readings of that sequence are both fair. The constructive one: the company raised equity at $1.00 and then at $1.50, took in another $15.0 million at $1.50 on a warrant exercise, and then raised debt at a 45 per cent premium instead of selling more stock — an improving cost of capital through the year. The cautious one: every one of those prices is above the $1.00 close of October 1, 2026, the remaining 10 million warrants at $1.50 are now well out of the money and expire in under a year, and the shelf has roughly $97.5 million of headroom left on a calculation the company does not itself publish.

04 Cash, burn and the going-concern conclusion

Cash rose $81.5 million in six months and none of it came from operations. The financing line brought in $115.4 million net — $23.2 million of stock, $15.0 million of warrant exercises, $117.0 million of notes net of discount, less $4.5 million of note issuance costs, $2.6 million of other issuance costs and the $32.7 million loan repayment. Investing was $27 thousand.

The burn, quarter by quarter

The two 2026 quarters are very different — $21.8 million then $12.2 million — and the filings do not reconcile the step down, so a reader should not annualise either one. Calculated, not disclosed: on the June quarter’s rate, $100.4 million is a little over eight quarters; on the first-half average of about $17.0 million, closer to six. Both figures sit before the cost of running three Phase 3 programmes at once, and before the $8.8 million of annual coupon on the notes, which begins to be paid in cash on November 15, 2026.

The runway statements, in order, because they have moved four times in eight months

For comparison, the March-quarter report was blunter than the June one: “As of March 31, 2026, the Company had an accumulated deficit of $427.2 million and cash totaling $31.9 million. This amount will not be sufficient to fund the Company’s operations over the next 12 months.” The note financing changed that sentence. It did not change the going-concern conclusion.

The revenue line, such as it is

There has never been any product revenue. The only revenue is non-cash collaborative arrangement revenue from the CanSinoBIO agreements: $1,533 thousand in the March quarter and $1,488 thousand in the June quarter, $4,413 thousand for 2025 against $4,055 thousand for 2024. One detail is worth printing because the annual report does not present it: the fourth quarter of 2025 carried negative revenue of $(193) thousand — a calculation from the full-year figure less the nine-month figure — which is a reversal of previously recognised collaborative revenue. No filing presents or explains a fourth-quarter revenue figure. Deferred revenue from the same arrangement stood at $4,170 thousand at June 30.

Against that, the June quarter carried $17,932 thousand of operating expenses — $10,690 thousand of research and $7,242 thousand of administration — and a net loss of $24,877 thousand, the largest in the periods shown, because it also absorbed $4,476 thousand of interest expense, the $2,383 thousand loss on extinguishing the Avenue loan and a $1,891 thousand adverse move in the derivative liability. Research spend by programme in 2025: OCU400 $9,871k, OCU410 and OCU410ST together $5,465k, NeoCart $295k, the inhaled vaccine platform $417k.

05 The pipeline, and one interim nobody should skip

Three gene therapies, all AAV-delivered modifier therapies licensed from a Harvard-affiliated eye institute, all in registrational trials. Then a protein, a vaccine platform funded by someone else, and a cartilage programme parked in a subsidiary. The useful way through it is by how close each is to a filing.

OCU400 — retinitis pigmentosa, the closest to a licence application

Gene-agnostic, addressing mutations across more than 100 genes. The Phase 3 trial is fully enrolled at 140 patients, randomised 2:1 against no treatment, dosed at 2.5×10¹⁰ vg per eye, open to early- to late-stage disease including children aged three and over. The primary endpoint is the 12-month change in functional vision measured by a luminance-dependent navigation assessment — a maze-mobility test under varying light levels — with the change in lux level as the secondary. Status: active, not recruiting. Topline guided to the first quarter of 2027; licence application to the second quarter of 2027, on a path the company says the agency has indicated could be rolling, with process performance qualification batches already complete.

What the record actually shows on efficacy is Phase 1/2 data at three years, and it is small. Of eight evaluable treated subjects, 88 per cent — seven of eight — showed improvement or preservation of visual function versus their own untreated fellow eye, with about a two-line gain across multiple mutation types. The evaluable population shrinks year by year as consent lapses: eleven at year one, eleven at year two, eight at year three. At twelve months the company reported 63 per cent of treated eyes improved from baseline and a statistically significant improvement in one mobility measure at p=0.031. Safety: zero serious adverse events related to OCU400.

Designations held: regenerative medicine advanced therapy and orphan drug in the United States, orphan medicinal product in Europe, and an advanced therapy classification from the European committee announced in February 2025.

OCU410ST — Stargardt disease, and the interim that used the word futility

This is the programme a reader should look at hardest, because it is the only one with a pivotal interim already read. The Phase 2/3 confirmatory trial is fully enrolled and dosed, randomised 2:1, primary endpoint the 12-month change in atrophic lesion size by fundus autofluorescence. Topline is guided to 2Q 2027 with a filing targeted mid-2027.

On September 3, 2026 the independent data monitoring committee completed a pre-specified interim analysis of lesion size in 26 subjects — 16 treated and 10 control — at eight months, and recommended the study continue per protocol to obtain eight-month follow-up on the whole population. The committee’s stated reasoning, verbatim and in full: it “noted that one could consider futility based on the negative direction of treatment effect on the interim sample and other interim results, but the DMC recommended the modification to obtain the entire dataset at 8 months in order to observe the results without the baseline lesion size imbalance that existed between the treatment and control arms in the small interim analysis population and that does not exist in the entire dataset at 8 months.” The company is following that recommendation.

That is not a futility stop and it should not be reported as one. It is also not nothing: a monitoring committee wrote negative direction of treatment effect into a public filing on the company’s lead confirmatory trial, and offered a baseline imbalance in a 26-patient subset as the reason to keep going. Both halves of that sentence belong in any summary of it.

The Phase 1 data it is built on is encouraging and very small — six evaluable patients at twelve months: atrophic lesion growth 54 per cent slower than the untreated fellow eye, ellipsoid-zone loss 116 per cent slower, about a one-line (six-letter) acuity gain, and 100 per cent of evaluable treated eyes stabilised or improved, with no serious adverse events. Two patients with worsening cataract and one lost to follow-up were excluded. No p-values are disclosed for any of those Phase 1 effect sizes. The work was published in a Nature-family ophthalmology journal in January 2026. Designations: orphan medicinal product in Europe (November 2024), rare paediatric disease designation (May 2025), and a European committee view in August 2025 accepting a single United States trial as the basis for a European application.

OCU410 — geographic atrophy, the strongest dataset and the newest trial

The Phase 2 result is the best-evidenced number in the company’s record, and it is worth stating only at the level the primary release supports. 51 patients aged 50 and over were randomised one-to-one-to-one — medium dose at 1×10¹⁰ vector genomes per eye, high dose at 3×10¹⁰, or no treatment — which is about 34 treated and 17 control. On the primary endpoint, the change in geographic-atrophy lesion area by fundus autofluorescence, the medium dose reduced growth 31 per cent versus control at p<0.05 in the evaluable set of 28 — 12 control and 16 on the medium dose. In the subset with lesions between 5 and 17.5 mm² the medium dose showed 33 per cent, with the release describing “similar reductions” in the high-dose group rather than giving a figure. The single responder figure the release states is that 55 per cent of treated patients achieved at least a 30 per cent lesion-size reduction versus control. An exploratory measure showed ellipsoid-zone loss 27 per cent slower, on an evaluable set of 25. On safety the fullest disclosure is the September presentation, which is the only source that breaks the population down by arm: 16 on the medium dose, 16 on the high dose and 13 controls, 45 in all. Against that population it reports no treatment-emergent serious adverse events, none considered severe, no endophthalmitis or retinal detachment, no vasculitis or vascular occlusion and no ischaemic optic neuropathy — and four choroidal neovascularisation adverse events: one on the medium dose, two on the high dose and one in the control arm, which it notes were not related to the drug on monitoring-committee review. The earlier March release also says there were “no cases of… choroidal neovascularization… reported to date,” but that clause sits inside a sentence about “the clean safety profile observed in Phase 1,” so it is not a statement about the Phase 2 population and this page does not set the two against each other. The four-event count stands on the September deck alone, and the fact that one of the four occurred in a group that received no treatment is the context that matters for reading it.

A Type B end-of-Phase-2 meeting with the agency’s biologics centre completed in July 2026 “resulting in alignment on all critical Phase 3 design elements, including primary and secondary endpoints, dose, adaptive design, and a single pivotal trial pathway to support a Biologics License Application.” The first Phase 3 patient was dosed on September 1, 2026: 237 patients, 2:1, at the medium dose that produced the result, adults 55 and over, primary endpoint the 12-month change in lesion size. A licence application is targeted for 2028.

The rest, briefly, because the rest is not what the stock turns on

• OCU200 — a recombinant fusion protein, not a gene therapy, in diabetic macular oedema and related indications. Phase 1, first patient dosed January 2025, enrolment expected complete in the first quarter of 2026. The only disclosure is safety: no serious adverse events and no related adverse events across the dose-escalation cohorts. No efficacy data of any kind exists in the record, and the programme does not appear in the September 2026 pipeline presentation.
• The inhaled vaccine platform — OCU500, OCU510, OCU520. The Phase 1 of the COVID-19 candidate is sponsored and fully funded by the United States National Institute of Allergy and Infectious Diseases, which covers “the full cost of the clinical trials, including operations and related analysis,” with Ocugen providing materials and retaining full right of reference to the findings. The flu and combination candidates remain preclinical. No clinical results have been disclosed for any vaccine candidate, and the filings carry an explicit demand risk following the end of the COVID-19 public health emergency. Research spend on the platform in 2025 was $417 thousand.
• NeoCart — an autologous cartilage cell therapy, Phase 3-ready and not initiated: “We intend to initiate the Phase 3 trial contingent on adequate availability of funding.” The assets were moved during 2025 into a wholly owned subsidiary. Its predecessor Phase 3, run by the company Ocugen reverse-merged into, “narrowly missed the primary endpoint” in 249 patients. Research spend in 2025: $295 thousand.
• One licence deal exists and it is the only commercial economics in the file. The company has disclosed a binding term sheet with Roots Pharmaceutical to license OCU400 in the Middle East and North Africa, carrying “up to $255 million in sales milestones and a 22 per cent royalty on net sales, as well as moderate upfront payment to Ocugen.” The upfront is not quantified, no definitive agreement has been disclosed, and no revenue has been recognised from it.
• A registered expanded-access programme also exists in the United States. The registry carries an expanded-access record for retinitis pigmentosa in adults with a status of available, separate from the Bahamian programme. Expanded access supplies patients, not revenue.
• COVAXIN — discontinued; the related preferred stock was redeemed in May 2024 and 2025 research spend on it was negative $2 thousand.

06 Register, insiders, short position and four lawsuits

The register turned institutional in the June quarter — and index money left before that

There is no Schedule 13D on this company — none filed in 2025 or 2026, the last amendment dating to 2019. So no activist and no strategic holder. What the passive filings show is a genuine rotation, and it runs in both directions.

One of those rows deserves a second look, and one does not. The one that does is Janus Henderson’s: its November 2025 filing reported 20,000,000 shares and no warrants, and its June 2026 amendment reports 10,000,000 — described in the filing itself as “10,000,000 common stock, including 10,000,000 Warrants”. On the face of those two filings the shares went and warrants took their place. The company has never named the counterparty to the August 2025 financing — the 8-K says only “an institutional investor” — so this page does not identify Janus Henderson as that investor, and a reader should treat any such identification as inference rather than record. The row that does not need a second look is Vanguard’s zero, for the reason given in the table: it is a disaggregation of reporting entities, not a disposal.

For completeness, the proxy’s own ownership table as of the July 27 record date lists three holders above five per cent — BlackRock at 7.95 per cent, Janus Henderson at 5.90 per cent and Millennium at 5.04 per cent — with all executive officers and directors as a group (seven persons) at 13,748,958 shares, 3.95 per cent, of which only 4,999,130 are actual shares; the rest is 8,741,878 option shares exercisable within sixty days and 7,950 warrant shares. The chief executive holds 9,815,476 beneficially, 2.84 per cent, of which 6,969,506 are options.

Insiders: one purchase, one large sale, and the purchase came from the newest officer

There is exactly one open-market purchase by any insider in the last twelve months. On June 15, 2026 the chief financial officer bought 21,000 shares at $1.23, taking her direct holding to 521,000. No pre-arranged plan is cited for it. She had filed her initial statement of holdings on March 5, 2026, on appointment, showing 500,000 shares and an option over 750,000 shares at $1.44.

The only open-market sales run the other way and are larger. On September 9, 2026 the chief executive sold 468,727 shares directly and 57,264 through a holding company — 525,991 shares in total — at a $1.12 weighted average, in multiple transactions between $1.06 and $1.31. A single Form 4 covers both lines and states the sales were made under a Rule 10b5-1 plan adopted on June 5, 2026. The $1.06-to-$1.31 range applies to the direct tranche; the 57,264 indirect shares went at $1.11 to $1.14. So the plan was adopted ten days before the chief financial officer bought, and executed three months later.

Everything else is grants. On January 2, 2026 the chief executive received a performance-unit award and an option over 3,123,201 shares at $1.38, vesting over three years from January 2027; the chief accounting officer received 207,300 restricted units and an option over 310,950 shares at the same price. On June 11, 2026 five directors each received an option over 170,100 shares at $1.22. A director exercised options over 194,134 shares at $0.46, $0.51 and $1.42 on April 1, 2026 with no accompanying sale reported. No transaction in the twelve months is coded as tax withholding.

The award pool, and why the authorised-share arithmetic does not work without the vote

The options are modestly in the money on paper — weighted $1.55 against $1.00 gives the stated intrinsic value only because a large tranche sits well below the average — and the exercisable portion at $1.90 is not. The number that compounds is the plan’s evergreen provision: 4 per cent of the prior year-end count added automatically each January, about 12.5 million shares this year. On a 339 million-share base that is a recurring claim on the authorised pool regardless of what the vote decides.

The short position is the largest number on this page after the notes

From 46,392,427 shares at the December 31 settlement to 106,062,298 on September 15 is an increase of about 129 per cent in under nine months, and the September figure is 31.3 per cent of the 339,044,893 shares outstanding — a calculation — and 32.1 per cent of the 330.6 million float. Two things make that unusual rather than merely large. The position built through the January and March equity raises and the May note issue, which is the ordinary signature of convertible-arbitrage hedging alongside directional short interest — and the notes were issued in May with no disclosed capped call or warrant hedge, so the hedging has to happen in the shares. And the days-to-cover figure swung from 28.24 to 10.39 in a fortnight purely because the reported 50-day average volume tripled around the September 3 interim and the adjourned meeting; the position itself grew. There is no figure for the September 30 settlement, which is published about eight business days after settlement.

Four live legal matters, and one that has already been decided

The accrual position is stated and it is nil: the company “believes that these lawsuits are without merit and intends to vigorously defend against them… No information is available to indicate that it is probable that a loss has been incurred and can be reasonably estimated.” No accrual has been recorded for any matter, and no insurance recovery is disclosed.

The fourth row is the one that bears directly on October 5. A company that had to obtain a judicial validation of its last authorised-share increase, after being accused of evading its own charter’s voting threshold, is now asking the same register for a much larger increase — under a threshold it has stated explicitly in the proxy, at a meeting it has already had to adjourn. That sequence is on the public record and this page draws no inference from it beyond printing it in order.

Management and the Nasdaq question

The chief executive is a co-founder and chairman and has held the role since the 2019 reverse merger. Below him the turnover in 2026 has been heavy, and it is not what a reader would guess from a company running three registrational trials.

• A new chief financial officer was appointed effective February 9, 2026, becoming principal financial officer immediately after the annual report was filed. She is the sole insider to have bought shares on the open market in the last twelve months.
• The chief medical officer separated effective May 8, 2026, with an acting chief medical officer appointed the same day and confirmed in the role effective June 11, 2026.
• The chief accounting officer resigned effective May 29, 2026, and the chief financial officer took on the principal accounting officer role as well on June 3, 2026.

So inside three weeks in May the company lost both its chief medical officer and its chief accounting officer, and one person now carries both the financial and the accounting officer roles. The proxy footnotes both departures. The board is set at six members in three classes of two, the chief executive included, and the five non-employee directors received identical option grants in June.

On the listing, the record is clean as at October 2, 2026 and the history is not. Ocugen has been through two complete minimum-bid-price cycles under Nasdaq Rule 5550(a)(2) — a deficiency in May 2023 cured in March 2024 after a second 180-day period, and another in December 2024 cured in July 2025, again after a second period had been granted. No deficiency is currently open. But the stock closed at $1.00 on October 1, and it has already closed below a dollar twice — $0.9935 on September 15 and $0.9984 on September 16, 2026, the two lowest closes of the past year, against a session low of $0.97 on the 16th — so the thirty-day count is a live question rather than a prospective one; a notice follows 30 consecutive business days below a dollar. Separately, shareholders’ equity is negative $16.6 million and no stockholders’-equity deficiency notice under Rule 5550(b) appears anywhere in the record — which is a fact about what has been filed, not a statement that the standard does not apply.

07 Catalyst map, red flags and the Merlintrader bottom line

The catalyst map

The nearest item is three days away and it is a shareholder vote. After that the calendar is empty of regulatory events until 2027, because nothing is filed.

Red flags

• The company’s own quarterly report concludes there is substantial doubt about its ability to continue as a going concern, and the auditor attached the same conclusion to the annual report in a separate explanatory section.
• Shareholders’ equity is negative $16.6 million and worsening from minus $12.2 million at the year end, on total assets of $124.2 million against liabilities of $140.8 million.
• $116.1 million of the $140.8 million of liabilities sits in current liabilities — $82.4 million of notes plus a $33.7 million derivative — against $100.4 million of cash, because the notes must be settled in cash until the share increase is effective.
• The indenture deadline of September 30, 2026 for obtaining that approval has already passed, leaving a “best efforts” obligation in its place.
• The first attempt at the vote could not have passed even unanimously. 160,214,431 shares were represented against a threshold of 169,555,201 — a shortfall of about 9.3 million votes before any ballot was counted — and 21 per cent of votes cast opposed even the adjournment.
• Abstentions count as votes against, and brokers already have discretion on the item, so there is no routing mechanism left to close the gap.
• Issued plus potentially dilutive shares come to about 461.6 million against 390,000,000 authorised — the company has committed more shares than it is permitted to issue.
• A December 31, 2026 deadline turns a failed vote into a cash cost: the chief executive becomes entitled to cash settlement of certain awards, plus interest and a tax gross-up.
• The monitoring committee on the lead confirmatory trial wrote that “one could consider futility based on the negative direction of treatment effect” on the 26-patient interim in Stargardt disease.
• No licence application has ever been filed for any programme, so there is no goal date, no advisory committee and no decision pending; the first submission is guided to the second quarter of 2027.
• Efficacy across the two closest programmes rests on very small evaluable populations — eight patients at three years for OCU400, six at twelve months for OCU410ST — and no p-values are disclosed for any of the OCU410ST Phase 1 effect sizes.
• Short interest is 106,062,298 shares, the peak of the published series, about 31.3 per cent of the count and 32.1 per cent of the float, up roughly 129 per cent since the December settlement.
• Four legal matters are live, including a securities class action awaiting a Third Circuit ruling that could revive a case dismissed with prejudice, and a Delaware derivative action alleging insider trading. No accrual has been recorded for any of them.
• The company had to obtain a judicial validation of its previous authorised-share increase after being accused of attempting to evade its charter’s voting threshold, and the court retained jurisdiction over a future fee application.
• Two completed Nasdaq minimum-bid-price cycles sit in the history, both requiring a second 180-day period to cure, and the stock closed at $1.00 on October 1, against a low of $0.97 on September 16, 2026. Separately, negative equity exists with no Rule 5550(b) notice on file.
• There is no at-the-market facility, so incremental equity has to be raised through announced transactions — and every price at which stock has been issued since August 2025 ($1.00, $1.50 and $1.50) is at or above the October 1 close.
• The chief medical officer and the chief accounting officer both left within three weeks in May 2026, and the chief financial officer appointed in February now holds the principal accounting officer role as well — at a company running three registrational trials.
• The only insider open-market purchase in twelve months is 21,000 shares, while the chief executive sold 525,991 shares on September 9 under a plan adopted in June.
• The equity plan adds 4 per cent of the outstanding count automatically every January — about 12.5 million shares this year — a standing claim on the authorised pool.
• The only revenue is a non-cash collaborative item, and it was negative $(193) thousand in the fourth quarter of 2025, a reversal the filings neither present nor explain.
• The chief executive received about 12.5 million performance units on a single day — the 3,123,201-unit regular annual award plus a further 9,369,604 units approved separately in December 2025 and granted January 2, 2026 “in addition to” it — alongside an option over 3,123,201 shares at $1.38. The 3,123,201 units do not appear in the performance-unit roll-forward, and no filing reconciles the two presentations.
• The note maturity is stated inconsistently within a single filing — May 15, 2034 in one place and July 15, 2034 in another.

What to watch, in order

1. The 8-K after October 5, and specifically whether it reports a result or another adjournment. This is the whole question, it is three days away, and the filing will be unambiguous. If it passes, watch next for the certificate of amendment being filed in Delaware — the vote authorises, the filing effects.
2. Whether the third-quarter report moves the notes out of current liabilities. That single reclassification, plus whatever happens to the $33.7 million derivative, is what turns negative equity positive. It is the cleanest test of whether the vote actually solved the problem it was called to solve.
3. The September cash figure and the burn. $100.4 million at June 30 less a quarter of three Phase 3 programmes, with the first coupon due November 15. The two 2026 quarters were $21.8 million and $12.2 million and the filings do not explain the difference, so the third is the one that establishes the real rate.
4. Any equity issuance, and at what price. There is no at-the-market facility, so it would have to be announced. A raise at or below $1.00 against the $1.50 and $1.00 of the last two deals would say the runway statement and the operating plan have diverged.
5. The full eight-month Stargardt dataset. The monitoring committee asked for it specifically because the interim carried a baseline imbalance. Whether the negative direction persists on the complete population is the single most informative clinical fact available before 2027.
6. The Third Circuit ruling. An affirmance closes the securities case and keeps three derivative actions stayed toward dismissal. A reversal revives all four.
7. Whether the chief financial officer buys again, and whether anyone joins her. One purchase of 21,000 shares against a 525,991-share sale by the chief executive is the entire insider signal of the last year.
8. The closing price relative to a dollar. Thirty consecutive business days below it starts a third listing cycle, and the company needed a second 180-day period in both previous cycles, taking about 209 days to cure the most recent one.
9. Full LARTA approval in The Bahamas, and whether any pricing is ever attached to it. Expanded access is not revenue; a disclosed price would be the first evidence that it could become revenue.
10. OCU400 topline in the first quarter of 2027. Far out, but it is the first event that makes the company something other than a capital-structure story.

Merlintrader bottom line

Ocugen is the rare biotech whose next binary event is written in corporate law rather than in a protocol. There is no application pending at any regulator — nothing has been filed for anything — so there is no goal date to wait for and nothing a reader can read across from an approval. What there is instead is a meeting on October 5, 2026, one proposal, and a threshold of 169,555,201 votes.

The case for taking the vote lightly is better than it first looks, and should be stated before the rest. On a cash-versus-burn basis the company is not in difficulty: $100.4 million at June 30 against a June-quarter burn of $12.2 million, a 12.25 per cent secured loan repaid in full and the lien over the assets released, and notes that nobody can convert before May 2027 and nobody would want to convert at $2.68 against a $1.00 share. Three programmes are in registrational trials rather than in slideware: OCU400 fully enrolled at 140 patients with manufacturing qualification complete and a rolling path indicated, OCU410 dosing a Phase 3 the agency aligned on in July after a Phase 2 that hit its primary endpoint at p<0.05, OCU410ST fully enrolled. And in the June quarter two of the largest index managers went from under two per cent to 8.0 and 6.3 per cent. On that reading, the current-liability classification is an accounting artefact of a clause one vote removes.

The case for taking it seriously is that the company itself does. Its own filing concludes there is substantial doubt about its ability to continue as a going concern, and the auditor said so too; equity is negative $16.6 million; the indenture deadline of September 30 has been missed; and the first attempt at the vote could not have passed even if every share in the room had voted yes. Three contracts now point at the same shortage — the notes’ cash-settlement requirement, the Nasdaq cap at 67,629,947 shares, and a December 31 letter agreement that converts a failed vote into a cash payment to the chief executive with interest and a tax gross-up. And the company has already been to a Delaware court once to validate an authorised-share increase after being accused of evading its charter’s voting threshold.

What the two cases have in common is that neither is about the medicine, and that is the real weakness here. The clinical evidence is genuinely promising and genuinely thin at the same time: the strongest dataset, OCU410 in geographic atrophy, is a 31 per cent lesion-growth reduction at p<0.05 in a 28-patient analysis, which is a real result in a hard indication; the closest-to-filing programme rests on eight evaluable patients at three years; and on the lead confirmatory trial a monitoring committee has put the words negative direction of treatment effect into a public filing. A reader should also not let the September headlines do more work than they can bear: a Bahamian provisional approval permitting expanded access, gated on a further approval that has not been granted, is not a launch, is not revenue, and is not an FDA or EMA action.

Which gives a test that needs no view on gene therapy at all. In the next five weeks there are three checkable things: whether the vote passes on October 5, whether the third-quarter report moves $116.1 million out of current liabilities and takes the equity deficit with it, and whether the company gets to the first coupon on November 15 without issuing stock below a dollar. If all three land, the going-concern language is an accounting consequence that has been cured and the story becomes OCU400’s topline in 1Q 2027. If the vote fails again, the questions stop being about accounting: a December 31 deadline, a 31 per cent short position, a $0.97 low and no at-the-market facility are a difficult combination to refinance out of, and the alternative route the indenture always allowed — a reverse split — solves the share shortage from the other direction, at a price.

None of the above is a recommendation, a target, or a view on the share price. It is a description of what is documented, what is guided, what is calculated and labelled as such, and what the record does not say.